Table 1.
Pharmacokinetic parameters (mean ± SD) of CBD in 6 dogs administered a single dose of CBD intranasally (20 mg) (IN) and orally (100 mg) (PO).
| Pharmacokinetic parameter | IN | PO |
|---|---|---|
| AUC(0−∞) (ng/mL*h)* | 61.31 ± 88.22 | 1376.03 ± 828.95 |
| Cmax (ng/mL)* | 27.96 ± 25.29 | 216.76 ± 108.51 |
| AUC(0−∞) (ng/mL*h)** | 3.06 ± 4.41 | 13.76 ± 8.28 |
| Cmax (ng/mL)** | 1.39 ± 1.26 | 2.16 ± 1.08 |
| Tmax (h)† | 0.49 ± 0.29 | 3.50 ± 0.55 |
| T1/2el (h) | 7.02 ± 7.97 | 15.65 ± 2.82 |
| kel (1/h) | 0.52 ± 0.54 | 0.045 ± 0.007 |
| MRT (h) | 10.30 ± 14.04 | 13.07 ± 3.61 |
| Relative F (%) | 22.28% | / |
AUC(0−∞), area under the plasma concentration-time curve from 0 to infinity post-administration; Cmax, maximal plasma concentration; Tmax, time to maximal plasma concentration; T1/2el, terminal elimination half-life; kel, elimination rate constant; MRT, mean residence time; F, absolute bioavailability.
*
Doses for AUC(0−∞) and Cmax before dose normalization.
**
Doses for AUC(0−∞) and Cmax after dose normalization to 1 mg CBD.
†
Significant differences between administration routes.